# A Safety and Efficacy Study of OnabotulinumtoxinA in Premature Ejaculation

> **NCT01917006** · PHASE2 · TERMINATED · sponsor: **Allergan** · enrollment: 59 (actual)

## Conditions studied

- Premature Ejaculation

## Interventions

- **DRUG:** OnabotulinumtoxinA
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT01917006
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-08-07
- **Primary completion:** 2017-08-15
- **Final completion:** 2017-08-15
- **Target enrollment:** 59 (ACTUAL)
- **Why stopped:** Strategic business decision was made to terminate the program. There were no safety concerns.
- **Last updated:** 2018-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01917006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01917006, "A Safety and Efficacy Study of OnabotulinumtoxinA in Premature Ejaculation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01917006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*